clinical application of platelet substitutes for control of post-cardiopulmonary bypass coagulopathy

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K17734
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 55030:Cardiovascular surgery-related
• Research Institution: National Defense Medical College
• Principal Investigator: Ishida Osamu 防衛医科大学校(医学教育部医学科進学課程及び専門課程、動物実験施設、共同利用研究施設、病院並びに防衛, 病院 外科, 講師 (20365266)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 血小板 / 人工血液 / 心臓血管外科 / 凝固障害 / 止血

Outline of Final Research Achievements

In order to prepare for the clinical application of H12-(ADP)-liposome administration, this study was conducted as a preliminary study for the clinical trial of H12-(ADP)-liposomes. The effect of H12-(ADP)-liposomes on coagulative function was investigated in vitro using perioperative blood samples from cardiovascular surgery patients with artificial heart-lungs. The results showed that H12-(ADP)-liposomes did not cause excessive platelet activation or hypercoagulable states and showed a certain degree of safety. The study has yielded useful results for the forthcoming clinical application of the world's first artificial platelet substitutes.

Free Research Field

心臓血管外科

Academic Significance and Societal Importance of the Research Achievements

我が国では近い将来少子高齢化のため、献血に依存する血液製剤の不足が予想されるが、人工血液製剤は有効な代替物として期待される。人工血小板製剤H12-(ADP)-リポソーム投与は、心臓血管外科手術患者に重大な副作用を引き起こすことなく安全に使用できることが示唆された。本研究は、来る世界初の人工血小板製剤の臨床応用に向けた有益な成果をもたらした。